

9 December  
2020

## Completion of Unmarketable Parcel Share Sale Facility

ASX Code: MXC

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

**MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company')**, a European based bio-pharma company specialising in the production and development of phytocannabinoid derived medicines, confirms that further to the announcements released 22 June 2020 and 26 October 2020, that the sale of 50,696,634 fully paid ordinary shares pursuant to the Company's Unmarketable Parcel Sale Facility (UMP Facility) has today been completed.

The UMP Facility applied to shareholders who as at 19 June 2020 (Record Date) were holders of shares in MGC Pharma with a market value of less than \$500. Under the UMP Facility the Company has arranged for the sale of the unmarketable parcels for a total 5,067 shareholders representing 50,696,634 shares, through an independent equity broker and the sale proceeds will be distributed by Computershare to each UMP Facility shareholder on a pro-rata basis. The sale of the UMP facility shares commenced on 11 August and was completed today, on the terms and conditions as previously announced, at an average price of 2.5 cents for the 50,696,634 UMP Facility shares.

Under the terms of the UMP Facility, there were 1,139 shareholders representing 12,480,489 shares that elected to continue holding MGC Pharma shares and 360 shareholders representing 4,663,914 shares that elected to top up their MGC Pharma share parcel to be above the market value of \$500 during the notice period.

Computershare will now complete a reconciliation of the UMP Facility share sales and prepare the formal documentation for the pro-rata distribution of proceeds to each UMP Facility shareholder, which is expected to be completed in approximately 1-2 weeks. UMP Facility shareholders can contact Computershare for further information as required.

MGC Pharma confirms its shareholder base has now been reduced by 5,067 shareholders. This will significantly reduce the Company's administrative and corporate costs moving forward.

--Ends--

**Authorised for release by the Board, for further information please contact:**

**PR/IR Advisors – Media & Capital Partners**

Melissa Hamilton (PR) +61 417 750 274

Rod Hinchcliffe (IR) +61 412 277 377

[Melissa.Hamilton@mcpartners.com.au](mailto:Melissa.Hamilton@mcpartners.com.au)

[Rod.Hinchcliffe@mcpartners.com.au](mailto:Rod.Hinchcliffe@mcpartners.com.au)

**MGC Pharmaceuticals Ltd**

Brett Mitchell

Executive Chairman

+61 8 6382 3390

[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

## About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. *Follow us through our social media channels*    